Cardiovascular Disease Risk Screening Guidelines

Core Blood Markers for Standard Screening

The American College of Cardiology recommends that all adults should have a fasting lipid profile measured starting at age 20 if risk factors are present, or at age 40 for men and age 45 for women without risk factors, repeated at least every 5 years 1, 2, 3
A fasting lipid profile is the cornerstone blood test and must include total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and non-HDL cholesterol 2, 3, 4, 5
Total cholesterol and HDL can be measured non-fasting if a fasting sample is unavailable, though fasting is preferred for complete assessment 1, 3
Abnormal results must be confirmed with a repeated sample on a separate occasion, using the average of both results for risk assessment 3
Fasting blood glucose should be measured at the same intervals as lipid screening (every 5 years, or every 2 years if risk factors present) 1, 4
Hemoglobin A1c should begin at age 40-70 years in adults with BMI ≥25 kg/m², or age 45 in those without risk factors 3
Serum creatinine with eGFR calculation is essential, as eGFR <60 mL/min/1.73 m² indicates chronic kidney disease and significantly elevated cardiovascular risk 4
Urinalysis with microalbuminuria assessment should be performed, particularly in patients with diabetes or hypertension 6, 4

The American Heart Association recommends that high-risk patients start comprehensive lipid and glucose screening at age 20 if any of the following risk factors are present: family history of premature CVD, diabetes mellitus, current cigarette smoking, hypertension, or obesity 1, 2, 3, 5
Average-risk men should begin lipid screening at age 35, while average-risk women should begin at age 45 2
All adults aged 40-75 should undergo lipid testing for comprehensive cardiovascular risk assessment 2, 3

The American College of Cardiology recommends that lipid profiles be repeated every 5 years in patients without risk factors 1, 2, 3
Patients with risk factors present or lipid levels close to treatment thresholds should undergo lipid profiling every 2 years 1, 3
More frequent testing (within 4-12 weeks) is recommended after initiating lipid-lowering therapy to assess response 5

The American Heart Association recommends that blood markers be combined with age, sex, blood pressure measurements, smoking status, presence of diabetes, and family history to calculate 10-year ASCVD risk 1, 6
Patients with ≥20% risk or diabetes are considered CHD risk equivalents requiring aggressive intervention 1, 6

All statements are derived from the cited references; specific levels of evidence were not detailed in the source material.